Forge Therapeutics awarded up to $17.2 million by NIH/NIAID for FG-LpxC, a novel antibiotic to treat antimicrobial resistance (AMR)
San Diego, California, September 29, 2022 – Forge Therapeutics, [...]
Forge Therapeutics achieves CARB-X milestone for FG-LpxC LUNG antibiotic program
San Diego, California, September 22, 2021 – Forge Therapeutics, [...]
Forge Therapeutics appoints Andrew Tomaras, Ph.D. as Chief Scientific Officer
San Diego, California, June 3, 2021 – Forge Therapeutics, [...]
Forge Enters Into Collaboration with Roche to Develop Novel Antibiotic to Treat Lung Infections
Forge is eligible to receive $190.5M in total payments SAN [...]
Forge Therapeutics receives notice of allowance from U.S. patent and trademark office covering novel chemistry targeting LpxC for the treatment of gram-negative bacterial infections
-Issuance of patent demonstrates utility of Forge’s BLACKSMITH chemistry [...]
Forge And Basilea Enter Into Multi-Target Agreement To Discover And Develop Novel Antibiotics
San Diego, California, April 24, 2019 – Forge Therapeutics, Inc. [...]
Forge Therapeutics to present at the 18th Annual Needham & Company Healthcare Conference
-Presentation will focus on Forge’s novel chemistry platform, BLACKSMITH, and [...]
Forge Receives Second CARB-X Award For Up To $11.1M To Accelerate Development Of Novel Antibiotic To Treat Lung Infections
San Diego, California, January 3, 2019 – Forge Therapeutics, Inc. [...]
Forge achieves carb-x milestone to advance its lpxc antibiotic to treat infections caused by the world’s deadliest ‘superbugs’
-Technical milestone achievement and program advancement from initial round of [...]
Forge announces presentations at upcoming scientific and industry meetings
2018 BIO International, ASM Microbe, and GRC Metals in Medicine [...]